Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-02-28
DOI
10.1007/s40262-019-00748-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- (2019) Edwin A. Basak et al. EUROPEAN JOURNAL OF CANCER
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
- (2018) Benjamin Ribba et al. CLINICAL CANCER RESEARCH
- The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
- (2018) Leire Ruiz-Cerdá et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
- (2018) Fei Tang et al. Cell and Bioscience
- Systems Pharmacology: Defining the Interactions of Drug Combinations
- (2018) J.G. Coen van Hasselt et al. Annual Review of Pharmacology and Toxicology
- Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle
- (2018) Imke H. Bartelink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Time Is Money: Optimizing the Scheduling of Nivolumab
- (2018) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of saturable distribution in compartmental PK models: dynamics and practical use
- (2017) Lambertus A. Peletier et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
- (2017) Hongshan Li et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Antibody Isotypes for Tumor Immunotherapy
- (2017) Anna Kretschmer et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- (2017) R. A. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC).
- (2017) Tim Maughan et al. JOURNAL OF CLINICAL ONCOLOGY
- A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients
- (2017) François Becher et al. Scientific Reports
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- (2016) M. Chatterjee et al. ANNALS OF ONCOLOGY
- Influence of immunoglobulin isotype on therapeutic antibody function
- (2016) Stephen A. Beers et al. BLOOD
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
- (2016) Morgane Caulet et al. CLINICAL PHARMACOKINETICS
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
- (2016) Emilie M.J. van Brummelen et al. ONCOLOGIST
- Understanding cachexia as a cancer metabolism syndrome
- (2016) P E Porporato Oncogenesis
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
- (2015) J. L. Lee et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology
- (2015) TH Oude Munnink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- (2015) Zeynep Eroglu et al. EUROPEAN JOURNAL OF CANCER
- Checkpoint inhibitors in Hodgkin's lymphoma
- (2015) Barbara Jezeršek Novaković EUROPEAN JOURNAL OF HAEMATOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities
- (2015) K Venkatakrishnan et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
- (2014) Yan Feng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
- (2014) Kayoko Waki et al. CANCER SCIENCE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
- (2014) T. Tawara et al. JOURNAL OF IMMUNOLOGY
- Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia
- (2013) J. G. Coen van Hasselt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Evolution of end points for cancer immunotherapy trials
- (2012) A. Hoos ANNALS OF ONCOLOGY
- Optimizing drug development of anti-cancer drugs in children using modelling and simulation
- (2012) Johan G.C. van Hasselt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody
- (2012) Lubna Abuqayyas et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics
- (2009) Leonid Gibiansky et al. Expert Opinion on Drug Metabolism & Toxicology
- Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
- (2009) Tanja Schneider-Merck et al. JOURNAL OF IMMUNOLOGY
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started